Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) is advancing a novel oncology approach that could reshape how certain cancers are treated. In a recent episode of the IBN BioMedWire Podcast, Chief Medical Officer Dr. Islam Mohamed detailed the company's lead drug candidate, ONC010, which targets the DNA repair enzyme polynucleotide kinase phosphatase (PNKP). The discussion, disseminated on behalf of Onco-Innovations, also covered the planned first-in-human clinical program for the drug.
ONC010 employs two distinct selectivity mechanisms designed to enhance its safety and efficacy. The first, synthetic lethality, aims to limit the drug's lethal effects to cancer cells that have lost PTEN or SHP-1, two tumor suppressor proteins. This means the drug should preferentially kill cancer cells with these specific genetic defects while sparing healthy cells. The second mechanism uses nanoparticle delivery to concentrate the drug within tumor tissue, further reducing systemic exposure and potential side effects.
Preclinical research conducted at the University of Alberta demonstrated that the nano-formulated PNKP inhibitor exhibited single-agent antitumor activity. In these studies, ONC010 was tolerated at tested doses and prolonged survival relative to controls. These findings provide a strong rationale for moving into human trials.
"The dual-selectivity approach of ONC010 represents a promising strategy in precision oncology," said Dr. Mohamed during the podcast. "By leveraging synthetic lethality and targeted delivery, we aim to create a therapy that is both potent against tumors and well-tolerated by patients."
Onco-Innovations holds an exclusive worldwide licence to patented technology directed to the therapeutic inhibition of PNKP, a novel clinical target in DNA damage response. The company is dedicated to cancer research and treatment, with a mission to pursue the prevention and treatment of cancer through pioneering research and innovative solutions.
For investors and industry observers, the advancement of ONC010 into clinical trials marks a critical milestone. If successful, the drug could offer a new treatment option for cancers characterized by PTEN or SHP-1 loss, which are common in several tumor types, including breast, prostate, and certain leukemias. The global oncology market continues to seek therapies with improved safety profiles, and ONC010's targeted approach could potentially address significant unmet needs.
The full press release can be viewed at https://ibn.fm/XgpMR. For ongoing updates, the company's newsroom is available at https://ibn.fm/ONNVF.
BioMedWire, the platform that hosted the podcast, is a specialized communications network focused on biotechnology, biomedical sciences, and life sciences. It is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions, article syndication to over 5,000 outlets, press release enhancement, social media distribution, and tailored corporate communications. More information is available at https://www.BioMedWire.com.
The development of ONC010 underscores the growing trend of precision medicine in oncology, where therapies are designed to exploit specific genetic vulnerabilities in cancer cells. As Onco-Innovations prepares for first-in-human studies, the results will be closely watched by researchers, clinicians, and investors alike. Success could validate PNKP as a viable target and open new avenues for combination therapies. However, challenges remain, including the need to demonstrate safety and efficacy in humans, navigate regulatory pathways, and ultimately commercialize the therapy in a competitive landscape.
